ReviewHepatic medicine : evidence and research2012
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics.
Review in Hepatic medicine : evidence and research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma.Irish journal of medical science · 2026Pooled it
- Diagnostic Value of Circulating microRNAs for Hepatocellular Carcinoma: Results of a Meta-analysis and Validation.Biochemical genetics · 2026Pooled it
- Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review.International journal of molecular sciences · 2022Pooled it
- The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.Frontiers in immunology · 2022Pooled it
- Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Disease markers · 2017Pooled it
- Integrated Bioinformatics and Multi-Omics Analysis of ZBTB40 Expression, Prognostic Relevance, and Regulatory Networks in Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Global changes in gene expression and splicing in alcoholic liver disease.Scientific reports · 2026Article
- PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy.Journal for immunotherapy of cancer · 2026Article
- Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE.BMC gastroenterology · 2025Article
- Global Changes in Gene Expression and Splicing in Alcoholic Liver Disease.Research square · 2025Article
- MicroRNA Landscape in Hepatocellular Carcinoma: Metabolic Re-Wiring, Predictive and Diagnostic Biomarkers, and Emerging Therapeutic Targets.Biomedicines · 2025Review
- Tumor Prognostic Risk Model Related to Monocytes/Macrophages in Hepatocellular Carcinoma Based on Machine Learning and Multi-Omics.Biological procedures online · 2025Article
- Identification of novel microRNAs: Biomarkers for pathogenesis of hepatocellular carcinoma in mice model.Biochemistry and biophysics reports · 2025Article
- LINC00667: A Novel Vital Oncogenic LincRNA.Current medicinal chemistry · 2025Review
- Clinical validation of peripheral blood mononuclear cell DNA methylation markers for accurate early detection of hepatocellular carcinoma in Asian patients.Communications medicine · 2024Article
- Integrative analysis of bulk and single-cell transcriptomic data reveals novel insights into lipid metabolism and prognostic factors in hepatocellular carcinoma.Discover oncology · 2024Article
- Molecular interactions between metformin and D-limonene inhibit proliferation and promote apoptosis in breast and liver cancer cells.BMC complementary medicine and therapies · 2024Article
- Circulating miRNA's biomarkers for early detection of hepatocellular carcinoma in Egyptian patients based on machine learning algorithms.Scientific reports · 2024Article
- RP11-495P10.1 promotes HCC cell proliferation by regulating reprogramming of glucose metabolism and acetylation of the NR4A3 promoter via the PDK1/PDH axis.Acta biochimica et biophysica Sinica · 2024Article
- Application of the Human Amniotic Membrane as an Adjuvant Therapy for the Treatment of Hepatocellular Carcinoma.Advances in experimental medicine and biology · 2024Review
108 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy in developing countries and its incidence is on the rise in the developing world. The epidemiology of this cancer is unique since its risk factors, including hepatitis C and B, have been clearly established. The current trends in the shifting incidence of HCC in different regions of the world can be explained partly by the changing prevalence of hepatitis. Early detection offers the only hope for curative treatment for patients with HCC, hence effective screening strategies for high-risk patients is of utmost importance. Liver transplantation and surgical resection remains the cornerstone of curative treatment. But major advances in locoregional therapies and molecular-targeted therapies for the treatment of advanced HCC have occurred recently. In this review, current trends in the worldwide epidemiology, surveillance, diagnosis, standard treatments, and the emerging therapies for HCC are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.